Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Sensipar N-[(1R)-1-naphthalen-1- ylethyl]-3-[3...

Synonyms: Mimpara, Parareg, Regpara, CNC-HCl, Cinacalcet HCl, ...

This record was replaced with 156419.

de Francisco, A.L., Shahapuni, I. et al., Strippoli, G.F. et al., Poon, G., Padhi, D. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on AMG 073

No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara) [1].
As suggested by its American brand name (Sensipar), the calcimimetic cinacalcet sensitizes the parathyroid cells to the extracellular calcium signal, suppressing parathyroid hormone (PTH) release and synthesis and preventing parathyroid cell proliferation [2].
SELECTION CRITERIA: We included all RCTs of any calcimimetic agent, cinacalcet HCl (AMG-073, Sensipar), NPS R-467 or NPS R-568 administered to patients with CKD for the treatment of SHPT [3].
Cinacalcet (Sensipar) is the first agent in its class that treats secondary hyperparathyroidism by increasing the sensitivity of calcium sensing receptors [4].

Anatomical context of AMG 073

A novel therapeutic, cinacalcet HCl (formerly AMG 073; Sensipar in the US and Mimpara in Europe; Amgen, Inc.), binds directly to the calcium-sensing receptor (CaR) on the cells of the parathyroid gland, increasing the receptor's sensitivity to calcium and reducing PTH, serum calcium and phosphorus levels [5].

References

No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara). Padhi, D., Harris, R.Z., Salfi, M., Sullivan, J.T. Clinical pharmacokinetics. (2005) [Pubmed]
How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Shahapuni, I., Mansour, J., Harbouche, L., Maouad, B., Benyahia, M., Rahmouni, K., Oprisiu, R., Bonne, J.F., Monge, M., El Esper, N., Presne, C., Moriniere, P., Choukroun, G., Fournier, A. Seminars in dialysis. (2005) [Pubmed]
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Strippoli, G.F., Tong, A., Palmer, S.C., Elder, G., Craig, J.C. Cochrane database of systematic reviews (Online) (2006) [Pubmed]
Cinacalcet hydrochloride (Sensipar). Poon, G. Proceedings (Baylor University. Medical Center) (2005) [Pubmed]
Cinacalcet HCl: a novel therapeutic for hyperparathyroidism. de Francisco, A.L. Expert opinion on pharmacotherapy. (2005) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share